Reaction Details | |||
---|---|---|---|
Report a problem with these data | |||
Target | Somatostatin receptor type 2 | ||
Ligand | BDBM50075285 | ||
Substrate/Competitor | n/a | ||
Meas. Tech. | ChEBML_200682 | ||
Ki | 40±n/a nM | ||
Citation | Pasternak, A; Pan, Y; Marino, D; Sanderson, PE; Mosley, R; Rohrer, SP; Birzin, ET; Huskey, SE; Jacks, T; Schleim, KD; Cheng, K; Schaeffer, JM; Patchett, AA; Yang, L Potent, orally bioavailable somatostatin agonists: good absorption achieved by urea backbone cyclization. Bioorg Med Chem Lett9:491-6 (1999) [PubMed] | ||
More Info.: | Get all data from this article, Assay Method | ||
Somatostatin receptor type 2 | |||
Name: | Somatostatin receptor type 2 | ||
Synonyms: | SOMATOSTATIN SST2 | SRIF-1 | SS-2-R | SS2-R | SS2R | SSR2_HUMAN | SSTR2 | Somatostatin receptor type 2 (SSTR2) | ||
Type: | Enzyme | ||
Mol. Mass.: | 41344.94 | ||
Organism: | Homo sapiens (Human) | ||
Description: | P30874 | ||
Residue: | 369 | ||
Sequence: |
| ||
BDBM50075285 | |||
n/a | |||
Name | BDBM50075285 | ||
Synonyms: | (2R,3S)-N-(5-Amino-[1,3]dioxan-2-ylmethyl)-3-(1H-indol-3-yl)-2-{2-oxo-3-[3-(2-oxo-2,3-dihydro-benzoimidazol-1-yl)-propyl]-imidazolidin-1-yl}-butyramide | CHEMBL341646 | ||
Type | Small organic molecule | ||
Emp. Form. | C30H37N7O5 | ||
Mol. Mass. | 575.6587 | ||
SMILES | C[C@H]([C@@H](N1CCN(CCCn2c3ccccc3[nH]c2=O)C1=O)C(=O)NC[C@H]1OC[C@H](N)CO1)c1c[nH]c2ccccc12 |wU:2.2,26.28,wD:29.32,1.0,(-1.63,3.05,;-1.61,1.51,;-.27,.75,;1.05,1.53,;1.03,3.07,;3.71,3.08,;3.72,1.54,;5.06,.79,;6.38,1.56,;7.73,.81,;9.05,1.58,;9.19,3.12,;8.15,4.25,;8.62,5.71,;10.13,6.06,;11.18,4.92,;10.69,3.45,;11.48,2.12,;10.46,.97,;10.79,-.54,;2.39,.76,;2.4,-.78,;-.27,-.78,;1.27,-.79,;-1.05,-2.11,;-.3,-3.45,;-1.07,-4.77,;-.3,-6.12,;-1.09,-7.45,;-2.64,-7.43,;-3.42,-8.76,;-3.38,-6.09,;-2.61,-4.77,;-2.94,.74,;-2.93,-.8,;-4.26,-1.59,;-5.59,-.82,;-6.93,-1.59,;-8.26,-.82,;-8.26,.72,;-6.93,1.51,;-5.59,.74,)| | ||
Structure |